Evidence map›Paper›PMID 40140918›Full record

ArticleArthritis research & therapy2025

Predicting rheumatoid arthritis progression from seronegative undifferentiated arthritis using machine learning: a deep learning model trained on the KURAMA cohort and externally validated with the ANSWER cohort.

Takayuki Fujii, Koichi Murata, Hirohiko Kohjitani, Akira Onishi, Kosaku Murakami, Masao Tanaka, Wataru Yamamoto, Koji Nagai, Ayaka Yoshikawa, Yuki Etani and 10 more

Abstract readValidation Study
In one paragraph

Article in Arthritis research & therapy, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 9 papers, 1 of them a synthesis that pooled it.

0numbers the graph read from it
0cells of the map it votes in
9citing papers in PubMed, 1 pooled it
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

9 citing papers in PubMed, 1 synthesis or guideline pooled it.

  1. Pooled it
  2. Article
  3. Article
  4. Review
  5. Observational
  6. Article
  7. Article
  8. Review
  9. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

20 authors.

Takayuki FujiiDepartment of Advanced Medicine for Rheumatic Diseases, Graduate School of Medicine, Kyoto University, 54 Shogoin Kawaharacho, Sakyo, Kyoto, Japan. fujiit@kuhp.kyoto-u.ac.jp.
Koichi MurataDepartment of Advanced Medicine for Rheumatic Diseases, Graduate School of Medicine, Kyoto University, 54 Shogoin Kawaharacho, Sakyo, Kyoto, Japan.
Hirohiko KohjitaniDepartment of Biomedical Data Intelligence, Graduate School of Medicine, Kyoto University, Kyoto, Japan.
Akira OnishiDepartment of Advanced Medicine for Rheumatic Diseases, Graduate School of Medicine, Kyoto University, 54 Shogoin Kawaharacho, Sakyo, Kyoto, Japan.
Kosaku MurakamiCenter for Cancer Immunotherapy and Immunobiology, Graduate School of Medicine, Kyoto University, Kyoto, Japan.
Masao TanakaDepartment of Advanced Medicine for Rheumatic Diseases, Graduate School of Medicine, Kyoto University, 54 Shogoin Kawaharacho, Sakyo, Kyoto, Japan.
Wataru YamamotoDepartment of Health Information Management, Kurashiki Sweet Hospital, Kurashiki, Japan.
Koji NagaiDepartment of Internal Medicine (IV), Osaka Medical and Pharmaceutical University, Takatsuki, Japan.
Ayaka YoshikawaDepartment of Internal Medicine (IV), Osaka Medical and Pharmaceutical University, Takatsuki, Japan.
Yuki EtaniDepartment of Sports Medical Biomechanics, Osaka University Graduate School of Medicine, Suita, Japan.
Yasutaka OkitaDepartment of Respiratory Medicine and Clinical Immunology, Osaka University, Suita, Japan.
Naofumi YoshidaFirst Department of Internal Medicine, Kansai Medical University, Hirakata, Japan.
Hideki AmuroFirst Department of Internal Medicine, Kansai Medical University, Hirakata, Japan.
Tadashi OkanoCenter for Senile Degenerative Disorders (CSDD), Osaka Metropolitan University Graduate School of Medicine, Osaka, Japan.
Yo UedaDepartment of Rheumatology and Clinical Immunology, Kobe University Graduate School of Medicine, Kobe, Japan.
Takaichi OkanoDepartment of Clinical Laboratory, Kobe University Hospital, Kobe, Japan.
Ryota HaraDepartment of Orthopaedic Surgery, Nara Medical University, Kashihara, Japan.
Motomu HashimotoDepartment of Clinical Immunology, Osaka Metropolitan University, Osaka, Japan.
Akio MorinobuDepartment of Rheumatology and Clinical Immunology, Kyoto University, Kyoto, Japan.
Shuichi MatsudaDepartment of Orthopaedic Surgery, Graduate School of Medicine, Kyoto University, Kyoto, Japan.

Funding

Japan Society for the Promotion of Science 22K16359
6 · The paper itself

Abstract

backgroundUndifferentiated arthritis (UA) often develops into rheumatoid arthritis (RA), but predicting disease progression from seronegative UA remains challenging because seronegative RA often does not meet the classification criteria. This study aims to build a machine learning (ML) model to predict the progression from seronegative UA to RA using clinical and laboratory parameters.

methodsKURAMA cohort (training dataset) and ANSWER cohort (validation dataset) were utilized. Patients with seronegative UA were selected based on specific inclusion and exclusion criteria. Clinical and laboratory parameters, including demographic data, acute phase reactants, autoantibodies, and physical examination findings, were collected. Various ML models, including a Feedforward Neural Network (FNN), were developed and compared. Model performance was evaluated using the area under the receiver operating characteristic curve (AUC), sensitivity, and other metrics. SHapley Additive exPlanations (SHAP) values were computed to interpret the importance of variables.

resultsKURAMA cohort included 210 patients with seronegative UA, of whom 57 (27.1%) progressed to RA. The FNN model demonstrated the highest predictive performance with an AUC of 0.924 and a sensitivity of 80.7% in the training dataset. Validation with ANSWER cohort (140 patients; 32.1% progressed to RA) showed an AUC of 0.777, sensitivity of 77.8%. MMP-3 had the highest impact on the model.

conclusionsThe FNN model exhibited robust performance in predicting the progression of RA from seronegative UA and maintained substantial sensitivity in an independent validation cohort. This model using only clinical and laboratory parameters has potential for predicting RA progression in patients with seronegative UA.

Indexed as

ArthritisArthritis, RheumatoidDeep LearningMachine LearningAdultAgedCohort StudiesDisease ProgressionFemaleHumansMaleMiddle Aged

Identifiers

PMID40140918
PMCPMC11938622

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.